FGFR1 and non-small cell lung carcinoma: We previously observed that NSCLC with amplification of FGFR1 were not dependent on E2 for release of FGFs and showed no increased anti-tumor effects when FGFR inhibitors were combined with fulvestrant (unpublished observations).